Member Info for Bighitter32

I invested before I got a taste of their marketing skills…. I expect it will get better.

I like the product, I have bought, tried and think they are reasonably priced…. But the LinkedIn graphic of the capsules, spray and drops with a red/white background and snowflakes in the foreground is just shocking. I don’t profess to be an expert at marketing or graphic design, but I certainly wouldn’t allow this into the general public. Tosh

I don’t do Facebook, twitter, instagram etc., but I keep a profile on LinkedIn….. I’m starting to see adverts and seasons greetings come up from CBX…. I’m one of the 988 followers…. Hmmmm

Anyway, in what I see, how cheap and tacky the graphics make the product look… if anyone from CBX is reading this, PLEASE STOP and think what you are doing.

I expect it depends….. The A class shares normally attract a 15% withholding tax, most class B shares are taxed via a self assessment tax return (assuming nit in a tax free wrapper).

The main reason AA got pushed aside, he demonstrated limited ability to execute…. The Board should also take some blame….. But at least they pulled in a new CEO well ahead of the investment community realising the gaps.
Some may say the soft launch was a test of the water in terms of execution, fair comment perhaps, but the first impression window has gone, the saving grace is the marketing was so light CBX are still pretty much anonymous to the general public and their targeted audience. This helps with the second bite of the cherry on execution…. Feb will define them to a fair extent, I don’t think all is lost, the Company can still shine.

Lol….. auto correct….. precedent not president!

Retain the choice but accept the consequences and specific personal contributions to health care cost is reasonable in my view. I’m with bald-eagle, and whilst the examples given on smoking, junk food etc are valid, they are not a president in this case.

Thanks for the update Lioness

Gjh, the data isn’t meaningless, if we are off to a good start then my own projections will change. We all gauge ‘investability’ of a company differently (not sure that’s a word?). I use some charts and reference data, but a lot of that is also ambiguous and on occasion quite academic, and often way off.

Thanks Lioness, great news. If you wouldn’t mind, can you share your order number (just to gauge again sales rates and/or verify volume assumptions). Thanks

RDS generally favour share buy backs as opposed to special dividends, they are also keen to lower gearing and as such prioritise reducing debt. A special dividend may come, but (in my view) is of low likelihood.
The whole landscape is in flux again, but mid/long term prospects for RDS is strong, their energy transition is in the implementation stage and the Traditional cash cow segments are delivering strong revenues . The recent alternative energy purchases are a bit of a low cost punt, but there is more behind their strategy than simply acquiring EV stations, wind farms etc…. They have a strong chance of success IMHO

Time for her to come out of the shadows and stamp her position and commitments to the flag pole…. Or practice the fine art of quiet leadership?

If they haven’t planned by now, with a suitable plan B and Plan C, then this magnificent board need a good reaming.

If they delay again then the bottom will fall out….. There has been more than enough time to get the logistics and supply chain sorted, and as mentioned, lockdowns will promote online ordering and self pampering.

Sorry…. Double post…. Must have had too much today

Quite a dry document…. If it does help then CBX should be all over it…. The markets today are saying it’s not beneficial.
The summary was not too strong….. “The Working Group concluded that it is very unlikely that plant-derived consumer CBD products would contain sufficient controlled phytocannabinoids (apart from ?9- THC) to produce any pronounced psychoactive effects unless they were purposely added to the product”….. I suspect a tighter and repeatable control level would have helped us.

One thing I did like is the following….. “As the popularity of consumer CBD products increases, the demand for synthetic CBD is likely to increase and improved methods developed (Bloemendal et al., 2021)”

Overall I’m indifferent to the report in terms of CBX benefit… but indeed, I did fall asleep reading it.

Quite a dry document…. If it does help then CBX should be all over it…. The markets today are saying it’s not beneficial.
The summary was not too strong….. “The Working Group concluded that it is very unlikely that plant-derived consumer CBD products would contain sufficient controlled phytocannabinoids (apart from ?9- THC) to produce any pronounced psychoactive effects unless they were purposely added to the product”….. I suspect a tighter and repeatable control level would have helped us.

One thing I did like is the following….. “As the popularity of consumer CBD products increases, the demand for synthetic CBD is likely to increase and improved methods developed (Bloemendal et al., 2021)”

Overall I’m indifferent to the report in terms of CBX benefit… but indeed, I did fall asleep reading it.

Would be good to have a very clear trading update at the AGM and also a ROM forecast, with a defined timeline (linked back to AA’s 250,000 comments)….. I really hope the numbers below are cycled as someone mentioned, otherwise the volumes appear quite weak.

Mine sent direct via the link in the RNS.

I know someone also asked this, but to get a gauge on order traction, anybody recently purchased and willing to share their order number?

I think the recent comments have been balanced, one or two perhaps negative, but also a few on the more cavalier side. Each to their own and keep going I say….. To live in a world of overly positive must be horrible, I’m not going there :-).
Constructive criticism needs to continue, as does positive encouragement. Having one without the other misses the essence of this Board.